Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Ovarian cancer, particularly epithelial ovarian cancer (EOC), is one of the deadliest gynecological malignancies due to nonspecific early symptoms and late diagnosis. Current diagnostic tools, while useful, often do not account for regional variations in disease presentation, particularly in Asian populations. This study aimed to develop and validate a new preoperative diagnostic index tailored to the Thai population by integrating complete blood count (CBC), tumor markers, and ultrasound features.
Methods: This retrospective cohort study included patients with pathologic pelvic or adnexal masses scheduled for surgery at Vajira Hospital from April 2022 to October 2024. Clinical data, CBC, cancer antigen 125 (CA125) levels, and ultrasound findings were analyzed to develop and validate a diagnostic index (KMUTT-NMU Diagnostic Index for Ovarian Cancer (KN-DIOC)). The model's performance was compared against established indices like Risk of Malignancy Index (RMI), Risk of Ovarian Malignancy Algorithm (ROMA), and Rajavithi-Ovarian Cancer Predictive Score (R-OPS) through multivariate logistic regression, focusing on key predictors.
Results: The study comprised 195 patients divided into 151 for the development dataset and 44 for the validation dataset. The KN-DIOC showed high discriminative ability with an area under curve (AUC) of 0.866, indicating very good capability in differentiating between benign and malignant ovarian masses. The index achieved a sensitivity of 93.75% and a specificity of 78.57%, demonstrating superior performance to traditional diagnostic tools, especially in the validation dataset.
Conclusion: The novel diagnostic index (KN-DIOC), incorporating CBC, ultrasound features, and tumor markers, provides a robust tool for preoperative assessment of ovarian tumors in Thai patients. It offers significant improvements in sensitivity and specificity over existing models, suggesting its potential for broader application in similar settings. This index supports enhanced decision-making in gynecological oncology, potentially leading to better patient outcomes through timely and accurate diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339250 | PMC |
| http://dx.doi.org/10.14740/wjon2595 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Nat Commun
September 2025
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, 90033, California, USA.
Availability of benign missense variant "truthsets" for validation of functional assays: Current status and a systematic approach.
Am J Hum Genet
September 2025
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Fulham Road, London, UK. Electronic address:
Multiplex assays of variant effect (MAVEs) provide promising new sources of functional evidence, potentially empowering improved classification of germline genomic variants, particularly rare missense variants, which are commonly assigned as variants of uncertain significance (VUSs). However, paradoxically, quantification of clinically applicable evidence strengths for MAVEs requires construction of "truthsets" comprising missense variants already robustly classified as pathogenic and benign. In this study, we demonstrate how benign truthset size is the primary driver of applicable functional evidence toward pathogenicity (PS3).
View Article and Find Full Text PDFPan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors.
Cell Rep Med
September 2025
Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway. Electronic address:
Accurate identification of tumor-specific markers is vital for developing chimeric antigen receptor (CAR)-based therapies. While cell surface antigens are seldom cancer-restricted, their post-translational modifications (PTMs), particularly aberrant carbohydrate structures, offer attractive alternatives. Among these, the sialyl-Tn (STn) antigen stands out for its prevalent presence in various epithelial tumors.
View Article and Find Full Text PDFEfficacy and safety of hyperthermic intraperitoneal intraoperative chemotherapy plus surgery in advanced ovarian cancer patients.
J Int Med Res
September 2025
Obstetrics and Gynecology Department, Wuhan University Zhongnan Hospital, China.
ObjectiveThis study aimed to evaluate the efficacy and safety of hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) in patients with advanced ovarian cancer.MethodsA total of 200 patients with advanced ovarian cancer were enrolled in this retrospective study and randomly allocated to two groups (research registry number: 11353). On the first day after abdominal closure, routine treatment was performed in the non-HIPEC group, whereas HIPEC was performed in the HIPEC group.
View Article and Find Full Text PDFMolecular impact of NOTCH signaling dysregulation on ovarian cancer progression, chemoresistance, and taxane response.
Biomed Pharmacother
September 2025
Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Laboratory of Pharmacogenomics, Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Electronic address:
Patients with epithelial ovarian cancer (EOC) face high mortality due to late diagnosis, recurrence, metastasis, and drug resistance. The NOTCH signaling pathway plays a critical role in cancer progression. This study analyzed NOTCH pathway deregulation in EOC patients and its response to taxane treatment in vitro and in vivo.
View Article and Find Full Text PDF